The Melanoma Tissue Bank: Progress Report
…some of melanoma’s most critical questions: Who will develop melanoma, and why? Whose melanomas will spread and become deadly? Which…
The Melanoma Tissue Bank: Progress Report
…some of melanoma’s most critical questions: Who will develop melanoma, and why? Whose melanomas will spread and become deadly? Which…
,
,
AIM Launches a New Program That Addresses the Emotional Needs of Melanoma Patients
by Mara Klecker Amid the COVID-19 pandemic, AIM at Melanoma has redoubled its efforts to meet the needs of melanoma…
Survivor Spotlight: Mark Lewis, Stage III Melanoma Survivor
…a melanoma specialist. Mark and nephew, Gavin Aside from his brother, Mark didn’t know anyone who’d had melanoma. When his…
,
Donor Spotlight: Jeff Berg, Stage IV Melanoma Survivor
…caregivers that offers everything from yoga to group therapy. Similarly, Jeff contacted AIM while he was fighting melanoma. He found…
,
,
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
…potential to be practice-changing in uveal melanoma.” Uveal melanoma is a rare disease with a low mutational burden and a…
,
,
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
…a potential additive effect for early-line treatment of patients with melanoma. I look forward to investigating this treatment approach in…
,
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
…advanced melanoma earlier this year.“We are thrilled with FDA’s decision to grant both Fast Track and Orphan Drug Designation to…
,
,
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients
…their melanoma returning.” Patients will appreciate this new treatment option after a Stage IIB or IIC diagnosis. “Melanoma patients will…
,
,
Coolibar’s Generous Donation to the AIM at Melanoma Foundation
…at Melanoma’s Mission AIM at Melanoma Foundation is committed to supporting patients with melanoma, educating the public about sun safety,…
,
AIM at Melanoma’s 4th Annual Evening in Memory of Valerie Guild
On Saturday, May 31st, AIM supporters, including many influential figures in the melanoma community, gathered for AIM at Melanoma’s 4th…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026